9.2 Intravenous Induction Agents & Sedative-Hypnotics

9.2 Intravenous Induction Agents & Sedative-Hypnotics

Intravenous induction agents and sedative-hypnotics provide rapid transition from wakefulness to surgical unresponsiveness. Understanding their pharmacokinetic models, receptor interactions, organ-specific physiological effects, and toxic failure modes is essential for the Certified Anesthesia Technologist (Cer.A.T.T.). Technologists prepare emergency drug setups, program target-controlled and standard infusion pumps, anticipate hemodynamic collapse, and enforce infection control practices surrounding intravenous lipid formulations.

---

Pharmacokinetics: Three-Compartment Model, Redistribution & Context-Sensitive Half-Time

Intravenous induction agents are administered directly into the central intravascular volume, rapidly distributing through the body according to a three-compartment pharmacokinetic model:

THREE-COMPARTMENT PHARMACOKINETIC MODEL:

       PERIPHERAL COMPARTMENT 2          CENTRAL COMPARTMENT (V1)         PERIPHERAL COMPARTMENT 3
            (Muscle, Skin)                (Vessel-Rich Group: VRG)           (Fat, Vessel-Poor)
         [Intermediate Volume]           [Brain, Heart, Liver, Kidneys]       [Deep Storage Sink]
                   ^                                  |                                ^
                   |                                  |                                |
                   +<==== Rate Constants (k12/k21) ==>+<==== Rate Constants (k13/k31) =+
                                                      |
                                                      v (Rate Constant k10)
                                              ELIMINATION / CLEARANCE
                                             (Hepatic / Renal Metabolism)

The Vessel-Rich Group (VRG) and Redistribution

The central compartment (V₁) consists of the Vessel-Rich Group (VRG): the brain, heart, liver, and kidneys. Although the VRG represents only 10% of total body mass, it receives approximately 75% of resting cardiac output. Highly lipophilic induction drugs (such as propofol, etomidate, and ketamine) rapidly cross the blood-brain barrier, reaching peak effect-site concentration within 30 to 60 seconds (one arm-brain circulation time).

Termination of a single intravenous bolus dose of an induction agent is governed by redistribution, NOT by hepatic metabolism or renal elimination. Drug molecules diffuse down their concentration gradient out of the brain and blood into moderately perfused tissues (skeletal muscle, skin: V₂) and poorly perfused tissues (adipose tissue: V₃). As central plasma and brain concentrations drop below the waking threshold, the patient awakens within 5 to 10 minutes, even though a substantial fraction of the active drug remains unmetabolized in peripheral compartments.

Context-Sensitive Half-Time (CSHT)

When intravenous anesthetics are administered as continuous infusions over hours (such as during Total Intravenous Anesthesia [TIVA] or intensive care sedation), peripheral storage compartments become progressively saturated. The drug can no longer rapidly redistribute away from the central compartment. Under these conditions, awakening depends on metabolic clearance.

The Context-Sensitive Half-Time (CSHT) is defined as the time required for the central plasma drug concentration to decrease by 50% following the termination of an intravenous infusion of a specific duration (the "context"):

These values come from classic pharmacokinetic simulations and product labeling; individual patients vary widely.

---

Propofol (2,6-diisopropylphenol)

Propofol is the most widely utilized intravenous induction and maintenance agent in modern anesthesia practice.

Receptor Mechanism & Dosing

Propofol acts primarily by binding directly to the beta-subunit of the pentameric GABA-A receptor complex. This enhances the inhibitory actions of gamma-aminobutyric acid (GABA) by increasing transmembrane chloride ion conductance, which hyperpolarizes the postsynaptic neuronal membrane and suppresses central neurotransmission.

• Induction Dose: 1.5 to 2.5 mg/kg IV in healthy adults. Dose is reduced to 1.0 to 1.5 mg/kg in elderly, hypovolemic, or critically ill patients; dose is increased to 2.5 to 3.5 mg/kg in infants and young children due to larger central volume of distribution and higher clearance.
• Maintenance Infusion (TIVA): 100 to 200 mcg/kg/min (6 to 12 mg/kg/hr).
• MAC Sedation Infusion: 25 to 75 mcg/kg/min.
• Antiemetic Bolus: 10 to 20 mg IV; infusion at 10 to 30 mcg/kg/min.

Organ System Effects

• Cardiovascular: Produces the most pronounced hypotension among common induction agents. It triggers marked arterial and venous vasodilation by reducing sympathetic tone and causing direct vascular smooth muscle relaxation, leading to significant drops in systemic vascular resistance (SVR), preload, and afterload. It exerts a direct negative inotropic effect and blunts the baroreceptor reflex, frequently preventing compensatory tachycardia despite significant drops in mean arterial pressure.
• Respiratory: Causes dose-dependent respiratory depression and a high incidence of apnea (lasting 30 to 90 seconds following an induction bolus). It blunts the ventilatory response to both hypercapnia and hypoxemia, suppresses pharyngeal and laryngeal reflexes (facilitating laryngeal mask airway [LMA] insertion without muscle relaxants), and produces bronchodilation.
• Central Nervous System: Decreases cerebral metabolic rate of oxygen consumption (CMRO₂), cerebral blood flow (CBF), and intracranial pressure (ICP). If mean arterial pressure is maintained, cerebral perfusion pressure (CPP = MAP - ICP) is preserved, making it an excellent agent for neurosurgical procedures. It exhibits anticonvulsant properties at standard clinical doses.
• Antiemetic and Antipruritic Properties: Sub-hypnotic doses (10 to 20 mg IV) exert direct antiemetic activity by suppressing chemoreceptor trigger zone and vagal signaling, reducing postoperative nausea and vomiting (PONV). It also alleviates opioid- and cholestasis-induced pruritus.

Lipid Formulation, Injection Pain & Strict Aseptic Handling

Propofol is insoluble in aqueous solutions and is formulated as an oil-in-water emulsion containing 10% soybean oil, 2.25% glycerol, and 1.2% purified egg phosphatide (egg lecithin).

+-----------------------------------------------------------------------------+
|                  PROPOFOL EMULSION INFECTION CONTROL RULES                  |
| - Formulated without antimicrobial preservatives (or contains minimal EDTA/ |
|   sodium metabisulfite). Highly supportive of bacterial and fungal growth.  |
| - SINGLE-USE VIAL/SYRINGE RULE: Open ampules, vials, and drawn syringes     |
|   must be labeled and DISCARDED WITHIN 6 HOURS of opening.                  |
| - INFUSION RULE: Propofol infusion bags, bottles, and dedicated delivery    |
|   tubing must be DISCARDED WITHIN 12 HOURS of spike/initiation.             |
| - Always use strict aseptic technique; never access a single vial for       |
|   multiple patients.                                                        |
+-----------------------------------------------------------------------------+

Pain on Injection: Occurs in up to 70% of patients receiving propofol through small peripheral veins, caused by direct irritation of venous endothelial nociceptors and activation of the local plasma kallikrein-kinin cascade. Mitigation techniques include: utilizing a large antecubital vein, pre-administering intravenous lidocaine (20 to 40 mg) under a temporary venous tourniquet, mixing lidocaine directly into the propofol syringe (e.g., 2 mL of 1% lidocaine with 18 mL of propofol), or pre-treating with a short-acting opioid.

Propofol Infusion Syndrome (PRIS)

Propofol Infusion Syndrome is a rare, life-threatening metabolic failure syndrome triggered by prolonged, high-dose propofol infusions—classically defined as infusions exceeding 4 to 5 mg/kg/hr (>67 to 83 mcg/kg/min) for longer than 48 hours, although it can occur with shorter high-dose infusions.

PATHOPHYSIOLOGY OF PROPOFOL INFUSION SYNDROME (PRIS):

       High-Dose / Prolonged Propofol Infusion (>4-5 mg/kg/hr for >48h)
                                     |
                                     v
            INHIBITION OF MITOCHONDRIAL ELECTRON TRANSPORT CHAIN
       (Inhibits Complexes I, II, & IV + Blocks Fatty Acid Beta-Oxidation)
                                     |
                                     v
               INTRACELLULAR ATP DEPLETION & ENERGETIC STARVATION
                                     |
        +----------------------------+----------------------------+
        |                            |                            |
        v                            v                            v
  CARDIAC COLLAPSE             RHABDOMYOLYSIS            CELLULAR ACIDOSIS
- Refractory Bradycardia    - Muscle Breakdown        - Profound Lactic Acidosis
- Brugada-like ECG Pattern  - Hyperkalemia (K+ >6.5)  - Refractory Metabolic Shock
- Cardiogenic Shock         - Myoglobinuria / Acute
- Asystole                    Renal Failure (ATN)

• Clinical Manifestations:
  1. Refractory severe bradycardia resistant to atropine and pacing, often displaying a Brugada-like ECG pattern (right bundle branch block with ST elevation in leads V1–V3), progressing to asystolic cardiac arrest.
  2. Severe lactic metabolic acidosis refractory to sodium bicarbonate therapy.
  3. Rhabdomyolysis with massive elevations in serum creatine kinase (CK >10,000–50,000 U/L), hyperkalemia, and dark reddish-brown myoglobinuria.
  4. Acute renal failure secondary to myoglobin cast nephropathy and renal hypoperfusion.
  5. Hepatomegaly, hypertriglyceridemia, and hepatic steatosis.
• Cer.A.T.T. Management Protocols: Immediately discontinue the propofol infusion. Assist with transvenous pacing, prepare inotropes (epinephrine, milrinone), set up emergency continuous renal replacement therapy (CRRT) or hemodialysis to clear toxic free fatty acids and correct hyperkalemia/acidosis, and prepare for venoarterial extracorporeal membrane oxygenation (VA-ECMO) if hemodynamic collapse progresses.

---

Etomidate (Amidate)

Etomidate is a carboxylated imidazole derivative synthesized as a pure single isomer (R-isomer possesses 10 times the hypnotic potency of the S-isomer).

Receptor Mechanism & Clinical Niche

Etomidate binds selectively to the GABA-A receptor, allosterically potentiating GABA-mediated chloride conductance.

• Induction Dose: 0.2 to 0.3 mg/kg IV. Onset is rapid (30 to 60 seconds), with recovery of consciousness in 5 to 10 minutes driven by redistribution.
• Hemodynamic Profile: Etomidate's defining clinical hallmark is its exceptional cardiovascular stability. It causes minimal to no change in heart rate, mean arterial pressure, stroke volume, or cardiac output. Sympathetic outflow and baroreceptor reflexes remain completely intact.
• Primary Indications: Drug of choice for rapid sequence induction (RSI) in patients with severe cardiac disease (critical aortic stenosis, severe congestive heart failure, ischemic cardiomyopathy) and severe hypovolemic or hemorrhagic shock (trauma, ruptured abdominal aortic aneurysm).
• Central Nervous System: Decreases CMRO₂, CBF, and ICP while preserving cerebral perfusion pressure (CPP), making it safe for neurotrauma.

Adverse Effects & Adrenocortical Suppression

+-----------------------------------------------------------------------------+
|                     ETOMIDATE: CLINICAL FAILURE MODES                       |
| 1. ADRENOCORTICAL SUPPRESSION: Reversible inhibition of 11-beta-hydroxylase |
|    blocks conversion of 11-deoxycortisol to cortisol. Even a single         |
|    induction dose suppresses adrenal cortisol output for 6 to 24 hours.     |
| 2. HIGH PONV: Postoperative nausea and vomiting rates reach 30% to 40%.     |
| 3. MYOCLONUS: Involuntary muscle twitching occurs in 30% to 60% of patients |
|    due to subcortical disinhibition (blunted by prior fentanyl or rocuronium)|
| 4. INJECTION PAIN: Formulated in 35% propylene glycol (hyperosmolar, pH 6.9)|
|    causing severe local burning and superficial thrombophlebitis.           |
+-----------------------------------------------------------------------------+

Because of persistent adrenocortical suppression, etomidate is strictly contraindicated as a continuous infusion for ICU sedation. A 1980s study of critically ill trauma patients sedated with etomidate infusions found increased mortality linked to adrenal suppression, ending that practice.

---

Ketamine (Ketalar)

Ketamine is a phencyclidine (PCP) derivative that produces a unique clinical state known as dissociative anesthesia.

Receptor Mechanism & Dosing

Ketamine is a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor. It binds stereospecifically to the phencyclidine binding site inside the open calcium channel pore of the NMDA receptor complex, preventing the excitatory neurotransmitter glutamate from activating post-synaptic neurons. The S(+)-enantiomer possesses 3 to 4 times the analgesic and hypnotic potency of the R(-)-enantiomer and carries a lower incidence of emergence delirium.

• Intravenous Induction Dose: 1.0 to 2.0 mg/kg IV (onset 30 to 60 seconds; duration 10 to 15 minutes).
• Intramuscular Induction Dose: 4.0 to 6.0 mg/kg IM (onset 3 to 5 minutes; invaluable for uncooperative pediatric patients, autistic patients, or combative adults without established venous access).
• Subanesthetic Analgesic Dose: 0.1 to 0.5 mg/kg IV bolus or 2 to 5 mcg/kg/min infusion (provides profound opioid-sparing analgesia and prevents acute opioid-induced hyperalgesia).

The Dissociative Anesthetic State

Ketamine disrupts functional communication between the limbic system (which processes emotional awareness and sensory integration) and the thalamocortical projection system (which relays incoming sensory information). The patient appears clinically awake:

• Eyes may remain wide open with a slow, roving horizontal nystagmus.
• Corneal, cough, and swallowing reflexes remain preserved.
• Skeletal muscle tone is maintained (cataleptic posture).
• However, the patient is profoundly analgesic, completely amnestic, and entirely dissociated from the surrounding environment.

Organ System Effects

• Cardiovascular (Indirect Sympathomimetic vs. Direct Inotrope):
  • In patients with intact autonomic reserves, ketamine stimulates central sympathetic outflow and blocks neuronal reuptake of norepinephrine, leading to increases in heart rate, arterial blood pressure, cardiac output, and myocardial oxygen demand (MVO₂).
  • Critical Failure Mode in Shock: Ketamine is actually a direct myocardial depressant. In critically ill, catecholamine-depleted patients (e.g., end-stage septic shock, prolonged ICU hospitalization, severe chronic decompensated heart failure), the central sympathetic surge cannot occur. The unmasked direct myocardial depression dominates, causing immediate cardiovascular collapse and profound hypotension.
• Respiratory & Airway: Ketamine is a potent bronchodilator, relaxing bronchial smooth muscle via indirect beta-2 adrenergic stimulation and direct calcium inhibition. It is the induction agent of choice in patients with severe asthma or acute bronchospasm. Spontaneous ventilation and hypoxic drive are typically preserved at therapeutic doses.
• Hypersalivation (Sialorrhea): Ketamine strongly stimulates salivary and tracheobronchial gland secretions. Copious secretions in the hypopharynx can irritate vocal cords and provoke laryngospasm. Anesthesia teams routinely co-administer an anticholinergic agent—specifically glycopyrrolate (0.1 to 0.2 mg IV)—to dry secretions.
• Central Nervous System & Emergence Delirium: Ketamine causes cerebral vasodilation, increasing CMRO₂, CBF, and intracranial pressure (ICP), as well as intraocular pressure (IOP). Upon emergence, 10% to 30% of adult patients experience emergence delirium characterized by vivid dreams, floating sensations, visual hallucinations, and acute agitation. This is prevented or attenuated by co-administering midazolam (1 to 2 mg IV) or propofol.

---

Dexmedetomidine (Precedex)

Dexmedetomidine is an imidazole derivative that acts as a potent, highly selective alpha-2 adrenergic receptor agonist.

Receptor Specificity & Mechanism

Dexmedetomidine possesses an alpha-2 to alpha-1 selectivity ratio of 1620:1, making it approximately 8 times more selective than clonidine (220:1). It binds presynaptic alpha-2 receptors in the locus coeruleus of the brainstem, which inhibits adenylate cyclase, reduces intracellular cyclic AMP (cAMP), and blocks the release of norepinephrine from presynaptic noradrenergic nerve terminals.

LOCUS COERULEUS ALPHA-2 ACTIVATION:

Dexmedetomidine ---> Presynaptic Alpha-2 Receptor Activation in Locus Coeruleus
                                     |
                                     v
              Inhibition of Noradrenergic Neurotransmission
                                     |
                                     v
            "COOPERATIVE SEDATION" (Mimics Natural Non-REM Sleep)
          - Patient easily aroused by verbal stimulus or light tap
          - Fully cooperative and follows complex commands
          - Drifts effortlessly back to sleep when stimulation ceases
          - ZERO SIGNIFICANT VENTILATORY DEPRESSION (CO2 curve preserved)

Clinical Applications & Dosing

• Loading Dose: 0.5 to 1.0 mcg/kg IV administered slowly over 10 minutes.
• Maintenance Infusion: 0.2 to 0.7 mcg/kg/hr (up to 1.0 to 1.4 mcg/kg/hr in intensive care sedation).
• Primary Indications: Awake fiberoptic intubation (preserves spontaneous breathing while patient remains calm and cooperative), awake neurosurgical craniotomies, procedural sedation in patients with difficult airways, and bridging difficult extubations in the ICU.

Hemodynamic Signature: The Biphasic Blood Pressure Response

Rapid bolus administration of dexmedetomidine produces a characteristic biphasic hemodynamic response:

1. Phase 1 (Transient Hypertension): Rapid injection stimulates postsynaptic alpha-2b receptors located on peripheral vascular smooth muscle, triggering acute peripheral vasoconstriction, transient systemic hypertension, and reflex bradycardia.
2. Phase 2 (Sustained Hypotension & Bradycardia): Within minutes, central presynaptic alpha-2a agonism in the locus coeruleus and nucleus tractus solitarius dominates, reducing central sympathetic outflow and causing sustained reductions in mean arterial pressure and heart rate.

Safety Warning: Rapid intravenous push must be strictly avoided; rapid boluses have precipitated severe sinus bradycardia, advanced atrioventricular block, and asystolic arrest.

---

Midazolam (Versed)

Midazolam is the primary short-acting benzodiazepine used for preoperative anxiolysis, procedural sedation, and induction adjunct.

Chemical Structure & pH-Dependent Ring Closure

Midazolam contains an imidazole ring that undergoes reversible, pH-dependent structural alterations:

• In the Glass Ampule (pH < 4.0): The imidazole ring remains open, rendering the molecule water-soluble. Consequently, midazolam does not require irritating solvents (such as propylene glycol), preventing the severe injection pain and thrombophlebitis associated with diazepam.
• In Physiological Blood (pH 7.4): Upon intravenous injection, exposure to physiological blood pH causes the imidazole ring to close spontaneously. The closed-ring molecule becomes highly lipophilic, rapidly penetrating the blood-brain barrier to produce rapid-onset sedation.

Mechanism of Action & Dosing

Midazolam binds to the specific benzodiazepine allosteric binding pocket located between the alpha and gamma subunits of the GABA-A receptor. Benzodiazepine binding does not open the chloride channel directly; instead, it allosterically increases the frequency of chloride channel opening in response to endogenous GABA binding.

• Preoperative Sedation / Anxiolysis: 0.02 to 0.08 mg/kg IV (typical adult dose 1.0 to 2.5 mg IV titrated in 0.5–1.0 mg increments).
• Pediatric Oral Premedication: 0.5 to 0.75 mg/kg PO (maximum 20 mg), administered 20 to 30 minutes prior to surgery.
• Induction Dose: 0.15 to 0.35 mg/kg IV (rarely used for induction today due to slower onset and prolonged recovery compared to propofol).

Clinical Actions

Midazolam provides five distinct clinical actions: anxiolysis, anterograde amnesia, sedation, anticonvulsant activity, and central muscle relaxation. Notably, it preserves retrograde memory (events prior to drug administration are remembered), but reliably produces dense anterograde amnesia (blocking memory consolidation of intraoperative events). While midazolam causes minimal cardiovascular or respiratory depression when given alone, co-administration with opioids results in profound, synergistic respiratory depression and arterial hypotension.

Specific Benzodiazepine Antagonist: Flumazenil (Romazicon)

Flumazenil is a pure competitive antagonist that binds directly to the benzodiazepine site on the GABA-A receptor, displacing benzodiazepine molecules without triggering intrinsic receptor activation:

• Dosing & Titration: For reversal of procedural sedation, the labeled initial dose is 0.2 mg IV over 15 seconds. If the desired level of consciousness is not reached after 45 seconds, 0.2 mg doses may be repeated at 60-second intervals up to a total of 1.0 mg.
• Onset & Duration: Onset occurs within 1 to 2 minutes; however, flumazenil has an elimination half-life of only about 1 hour, shorter than most benzodiazepines.
• Critical Failure Mode (Resedation): Because the clinical duration of flumazenil is substantially shorter than that of midazolam (and other benzodiazepines like lorazepam or diazepam), the antagonist clears from the central nervous system while active benzodiazepine remains in the body. The patient may awaken fully, only to lapse back into coma and hypoventilation 60 minutes later. Continuous monitoring for at least 2 hours is required.
• Seizure Warning: Flumazenil is strictly contraindicated in patients receiving chronic benzodiazepines for seizure disorders or in suspected tricyclic antidepressant overdoses, as acute reversal triggers intractable grand mal status epilepticus.